The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the < 29 wGA group and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Capizzi, Antonino, Silvestri, Michela, Orsi, Andrea, Cutrera, Renato, Rossi, Giovanni A., Sacco, Oliviero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557508/
https://www.ncbi.nlm.nih.gov/pubmed/28807039
http://dx.doi.org/10.1186/s13052-017-0390-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557508/
https://www.ncbi.nlm.nih.gov/pubmed/28807039
http://dx.doi.org/10.1186/s13052-017-0390-8

Ejemplares similares